- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
BI-D1870
BI-D1870是一種ATP-競爭性S6 ribosome抑制劑，在無細胞試驗中作用于RSK1/2/3/K4，IC50分別為31 nM/24 nM/18 nM/15 nM，作用于RSK比作用于MST2，GSK-3β，MARK3，CK1和Aurora B選擇性高10到100倍。BI-D1870 顯示除了抗癌的屬性包括活性氧的生成、提高內(nèi)質(zhì)網(wǎng)應(yīng)激反應(yīng)和誘導(dǎo)自噬。
BI-D1870 Chemical Structure
CAS: 501437-28-1
產(chǎn)品質(zhì)控
批次：
純度：
99.75%
99.75
BI-D1870相關(guān)產(chǎn)品
| 相關(guān)靶點 | p70 S6K p70 S6K1 RSK1 RSK2 RSK3 RSK4 | 點擊展開 |
|---|---|---|
| 相關(guān)產(chǎn)品 | PF-4708671 LY2584702 LY2584702 Tosylate LJI308 LJH685 Phospho-S6K1(T421/S424) Rabbit Recombinant mAb | 點擊展開 |
| 相關(guān)化合物庫 | 激酶抑制劑庫 PI3K/Akt 抑制劑庫 凋亡分子化合物庫 細胞周期化合物庫 NF-κB信號通路庫 | 點擊展開 |
相關(guān)信號通路圖
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
|---|---|---|---|---|---|
| LNCaP-Clone-FGC | Growth Inhibition Assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 3.70041 μM. | SANGER | ||
| JEG-3 | Growth Inhibition Assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 3.6919 μM. | SANGER | ||
| LB2241-RCC | Growth Inhibition Assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50 = 3.68625 μM. | SANGER | ||
| NCI-H446 | Growth Inhibition Assay | Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50 = 3.6834 μM. | SANGER | ||
| HUTU-80 | Growth Inhibition Assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50 = 3.66621 μM. | SANGER | ||
| COLO-829 | Growth Inhibition Assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 3.66618 μM. | SANGER | ||
| KG-1 | Growth Inhibition Assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 3.61106 μM. | SANGER | ||
| KU-19-19 | Growth Inhibition Assay | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50 = 3.60304 μM. | SANGER | ||
| LB831-BLC | Growth Inhibition Assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50 = 3.54016 μM. | SANGER | ||
| TYK-nu | Growth Inhibition Assay | Inhibition of human TYK-nu cell growth in a cell viability assay, IC50 = 3.53676 μM. | SANGER | ||
| CAL-33 | Growth Inhibition Assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50 = 3.53362 μM. | SANGER | ||
| CHP-134 | Growth Inhibition Assay | Inhibition of human CHP-134 cell growth in a cell viability assay, IC50 = 3.48758 μM. | SANGER | ||
| Ca-Ski | Growth Inhibition Assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 3.47514 μM. | SANGER | ||
| BB65-RCC | Growth Inhibition Assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50 = 3.45396 μM. | SANGER | ||
| SW48 | Growth Inhibition Assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 3.43358 μM. | SANGER | ||
| RD | Growth Inhibition Assay | Inhibition of human RD cell growth in a cell viability assay, IC50 = 3.43132 μM. | SANGER | ||
| EW-11 | Growth Inhibition Assay | Inhibition of human EW-11 cell growth in a cell viability assay, IC50 = 3.41224 μM. | SANGER | ||
| RPMI-7951 | Growth Inhibition Assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50 = 3.3973 μM. | SANGER | ||
| MOLT-4 | Growth Inhibition Assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 3.39098 μM. | SANGER | ||
| SNU-C2B | Growth Inhibition Assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50 = 3.39097 μM. | SANGER | ||
| HD-MY-Z | Growth Inhibition Assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50 = 3.36542 μM. | SANGER | ||
| T98G | Growth Inhibition Assay | Inhibition of human T98G cell growth in a cell viability assay, IC50 = 3.28216 μM. | SANGER | ||
| GOTO | Growth Inhibition Assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 3.28004 μM. | SANGER | ||
| NCI-H810 | Growth Inhibition Assay | Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50 = 3.22155 μM. | SANGER | ||
| MKN1 | Growth Inhibition Assay | Inhibition of human MKN1 cell growth in a cell viability assay, IC50 = 3.20875 μM. | SANGER | ||
| TE-8 | Growth Inhibition Assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50 = 3.19231 μM. | SANGER | ||
| GI-1 | Growth Inhibition Assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50 = 3.15255 μM. | SANGER | ||
| KM12 | Growth Inhibition Assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 3.12273 μM. | SANGER | ||
| NH-12 | Growth Inhibition Assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 3.11456 μM. | SANGER | ||
| A427 | Growth Inhibition Assay | Inhibition of human A427 cell growth in a cell viability assay, IC50 = 3.10873 μM. | SANGER | ||
| GMS-10 | Growth Inhibition Assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 3.09388 μM. | SANGER | ||
| SCC-4 | Growth Inhibition Assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 3.09276 μM. | SANGER | ||
| D-502MG | Growth Inhibition Assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50 = 3.07019 μM. | SANGER | ||
| JVM-3 | Growth Inhibition Assay | Inhibition of human JVM-3 cell growth in a cell viability assay, IC50 = 3.06756 μM. | SANGER | ||
| PSN1 | Growth Inhibition Assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50 = 3.05786 μM. | SANGER | ||
| NCI-H1299 | Growth Inhibition Assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50 = 2.93736 μM. | SANGER | ||
| EM-2 | Growth Inhibition Assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 2.92193 μM. | SANGER | ||
| D-566MG | Growth Inhibition Assay | Inhibition of human D-566MG cell growth in a cell viability assay, IC50 = 2.91295 μM. | SANGER | ||
| SF268 | Growth Inhibition Assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50 = 2.87225 μM. | SANGER | ||
| SW954 | Growth Inhibition Assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50 = 2.8583 μM. | SANGER | ||
| HH | Growth Inhibition Assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 2.80001 μM. | SANGER | ||
| ME-180 | Growth Inhibition Assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50 = 2.77736 μM. | SANGER | ||
| EW-1 | Growth Inhibition Assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50 = 2.75328 μM. | SANGER | ||
| NCI-H1792 | Growth Inhibition Assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50 = 2.73738 μM. | SANGER | ||
| U251 | Growth Inhibition Assay | Inhibition of human U251 cell growth in a cell viability assay, IC50 = 2.73032 μM. | SANGER | ||
| 639-V | Growth Inhibition Assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 2.71703 μM. | SANGER | ||
| NCI-H69 | Growth Inhibition Assay | Inhibition of human NCI-H69 cell growth in a cell viability assay, IC50 = 2.71601 μM. | SANGER | ||
| HEL | Growth Inhibition Assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 2.70254 μM. | SANGER | ||
| NCI-H1048 | Growth Inhibition Assay | Inhibition of human NCI-H1048 cell growth in a cell viability assay, IC50 = 2.68321 μM. | SANGER | ||
| SJSA-1 | Growth Inhibition Assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50 = 2.6687 μM. | SANGER | ||
| ACN | Growth Inhibition Assay | Inhibition of human ACN cell growth in a cell viability assay, IC50 = 2.6679 μM. | SANGER | ||
| Becker | Growth Inhibition Assay | Inhibition of human Becker cell growth in a cell viability assay, IC50 = 2.66078 μM. | SANGER | ||
| Ca9-22 | Growth Inhibition Assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 2.65933 μM. | SANGER | ||
| LCLC-97TM1 | Growth Inhibition Assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 2.60028 μM. | SANGER | ||
| DB | Growth Inhibition Assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 2.55013 μM. | SANGER | ||
| COLO-800 | Growth Inhibition Assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 2.54166 μM. | SANGER | ||
| P12-ICHIKAWA | Growth Inhibition Assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50 = 2.52559 μM. | SANGER | ||
| HT-3 | Growth Inhibition Assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 2.51024 μM. | SANGER | ||
| H4 | Growth Inhibition Assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 2.48393 μM. | SANGER | ||
| NCI-H1395 | Growth Inhibition Assay | Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50 = 2.47121 μM. | SANGER | ||
| NB6 | Growth Inhibition Assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 2.45779 μM. | SANGER | ||
| MN-60 | Growth Inhibition Assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 2.44883 μM. | SANGER | ||
| HuO9 | Growth Inhibition Assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50 = 2.36824 μM. | SANGER | ||
| AGS | Growth Inhibition Assay | Inhibition of human AGS cell growth in a cell viability assay, IC50 = 2.34404 μM. | SANGER | ||
| GCT | Growth Inhibition Assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 2.31358 μM. | SANGER | ||
| SW1710 | Growth Inhibition Assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50 = 2.30661 μM. | SANGER | ||
| SK-N-AS | Growth Inhibition Assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50 = 2.29059 μM. | SANGER | ||
| D-283MED | Growth Inhibition Assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 2.23695 μM. | SANGER | ||
| ES5 | Growth Inhibition Assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50 = 2.23633 μM. | SANGER | ||
| 8-MG-BA | Growth Inhibition Assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50 = 2.23461 μM. | SANGER | ||
| TE-9 | Growth Inhibition Assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 2.17376 μM. | SANGER | ||
| HMV-II | Growth Inhibition Assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50 = 2.16633 μM. | SANGER | ||
| KYSE-150 | Growth Inhibition Assay | Inhibition of human KYSE-150 cell growth in a cell viability assay, IC50 = 2.15234 μM. | SANGER | ||
| BPH-1 | Growth Inhibition Assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50 = 2.12957 μM. | SANGER | ||
| G-361 | Growth Inhibition Assay | Inhibition of human G-361 cell growth in a cell viability assay, IC50 = 2.1221 μM. | SANGER | ||
| NB14 | Growth Inhibition Assay | Inhibition of human NB14 cell growth in a cell viability assay, IC50 = 2.11321 μM. | SANGER | ||
| DU-145 | Growth Inhibition Assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50 = 2.11056 μM. | SANGER | ||
| QIMR-WIL | Growth Inhibition Assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 2.07849 μM. | SANGER | ||
| LOXIMVI | Growth Inhibition Assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 2.04434 μM. | SANGER | ||
| SK-NEP-1 | Growth Inhibition Assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 2.044 μM. | SANGER | ||
| 697 | Growth Inhibition Assay | Inhibition of human 697 cell growth in a cell viability assay, IC50 = 2.02228 μM. | SANGER | ||
| BV-173 | Growth Inhibition Assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50 = 1.98666 μM. | SANGER | ||
| YKG-1 | Growth Inhibition Assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 1.98432 μM. | SANGER | ||
| NCI-H2029 | Growth Inhibition Assay | Inhibition of human NCI-H2029 cell growth in a cell viability assay, IC50 = 1.97241 μM. | SANGER | ||
| CHL-1 | Growth Inhibition Assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50 = 1.95792 μM. | SANGER | ||
| ES8 | Growth Inhibition Assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50 = 1.87724 μM. | SANGER | ||
| ES4 | Growth Inhibition Assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50 = 1.85143 μM. | SANGER | ||
| NBsusSR | Growth Inhibition Assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50 = 1.82961 μM. | SANGER | ||
| NB10 | Growth Inhibition Assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50 = 1.7763 μM. | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 1.70444 μM. | SANGER | ||
| NEC8 | Growth Inhibition Assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 1.70115 μM. | SANGER | ||
| A3-KAW | Growth Inhibition Assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 1.62834 μM. | SANGER | ||
| HN | Growth Inhibition Assay | Inhibition of human HN cell growth in a cell viability assay, IC50 = 1.61368 μM. | SANGER | ||
| KE-37 | Growth Inhibition Assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 1.59478 μM. | SANGER | ||
| BE-13 | Growth Inhibition Assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50 = 1.58709 μM. | SANGER | ||
| BFTC-905 | Growth Inhibition Assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50 = 1.56332 μM. | SANGER | ||
| LoVo | Growth Inhibition Assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 1.46755 μM. | SANGER | ||
| NCI-H292 | Growth Inhibition Assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50 = 1.46069 μM. | SANGER | ||
| CTB-1 | Growth Inhibition Assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50 = 1.44679 μM. | SANGER | ||
| A549 | Growth Inhibition Assay | Inhibition of human A549 cell growth in a cell viability assay, IC50 = 1.30955 μM. | SANGER | ||
| KOSC-2 | Growth Inhibition Assay | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50 = 1.13385 μM. | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 1.12794 μM. | SANGER | ||
| TGW | Growth Inhibition Assay | Inhibition of human TGW cell growth in a cell viability assay, IC50 = 1.05124 μM. | SANGER | ||
| EoL-1-cell | Growth Inhibition Assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 1.01878 μM. | SANGER | ||
| Daoy | Growth Inhibition Assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50 = 0.98767 μM. | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 0.97897 μM. | SANGER | ||
| ES7 | Growth Inhibition Assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50 = 0.91607 μM. | SANGER | ||
| KY821 | Growth Inhibition Assay | Inhibition of human KY821 cell growth in a cell viability assay, IC50 = 0.88812 μM. | SANGER | ||
| HL-60 | Growth Inhibition Assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 0.88362 μM. | SANGER | ||
| CAL-62 | Growth Inhibition Assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50 = 0.88152 μM. | SANGER | ||
| ML-2 | Growth Inhibition Assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.85575 μM. | SANGER | ||
| LU-139 | Growth Inhibition Assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50 = 0.84958 μM. | SANGER | ||
| IST-SL1 | Growth Inhibition Assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 0.84574 μM. | SANGER | ||
| HSC-3 | Growth Inhibition Assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50 = 0.81769 μM. | SANGER | ||
| MC-IXC | Growth Inhibition Assay | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50 = 0.79589 μM. | SANGER | ||
| NCI-H209 | Growth Inhibition Assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 0.7682 μM. | SANGER | ||
| GAMG | Growth Inhibition Assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50 = 0.74717 μM. | SANGER | ||
| ECC10 | Growth Inhibition Assay | Inhibition of human ECC10 cell growth in a cell viability assay, IC50 = 0.70094 μM. | SANGER | ||
| SBC-1 | Growth Inhibition Assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50 = 0.69524 μM. | SANGER | ||
| KP-N-YS | Growth Inhibition Assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50 = 0.68223 μM. | SANGER | ||
| KU812 | Growth Inhibition Assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50 = 0.62623 μM. | SANGER | ||
| EW-18 | Growth Inhibition Assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 0.62211 μM. | SANGER | ||
| A172 | Growth Inhibition Assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 0.51705 μM. | SANGER | ||
| DU-4475 | Growth Inhibition Assay | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50 = 0.50417 μM. | SANGER | ||
| CTV-1 | Growth Inhibition Assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 0.47872 μM. | SANGER | ||
| NCI-H720 | Growth Inhibition Assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50 = 0.17194 μM. | SANGER | ||
| KARPAS-45 | Growth Inhibition Assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 0.16525 μM. | SANGER | ||
| H9 | Growth Inhibition Assay | Inhibition of human H9 cell growth in a cell viability assay, IC50 = 0.06019 μM. | SANGER | ||
| EW-3 | Growth Inhibition Assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 0.0358 μM. | SANGER | ||
| M059J | Growth Inhibition Assay | Inhibition of human M059J cell growth in a cell viability assay, IC50 = 3.71468 μM. | SANGER | ||
| SK-MES-1 | Growth Inhibition Assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 3.7303 μM. | SANGER | ||
| GT3TKB | Growth Inhibition Assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 3.75604 μM. | SANGER | ||
| DOK | Growth Inhibition Assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 3.76526 μM. | SANGER | ||
| HO-1-N-1 | Growth Inhibition Assay | Inhibition of human HO-1-N-1 cell growth in a cell viability assay, IC50 = 3.79801 μM. | SANGER | ||
| MZ1-PC | Growth Inhibition Assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 3.82883 μM. | SANGER | ||
| 8305C | Growth Inhibition Assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 3.88943 μM. | SANGER | ||
| CGTH-W-1 | Growth Inhibition Assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50 = 3.93504 μM. | SANGER | ||
| LU-134-A | Growth Inhibition Assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 3.95422 μM. | SANGER | ||
| C32 | Growth Inhibition Assay | Inhibition of human C32 cell growth in a cell viability assay, IC50 = 3.96581 μM. | SANGER | ||
| MOLT-13 | Growth Inhibition Assay | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50 = 3.96856 μM. | SANGER | ||
| A375 | Growth Inhibition Assay | Inhibition of human A375 cell growth in a cell viability assay, IC50 = 4.05162 μM. | SANGER | ||
| CAL-12T | Growth Inhibition Assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50 = 4.05795 μM. | SANGER | ||
| IGR-1 | Growth Inhibition Assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 4.10274 μM. | SANGER | ||
| LB1047-RCC | Growth Inhibition Assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 4.10441 μM. | SANGER | ||
| BHT-101 | Growth Inhibition Assay | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50 = 4.10683 μM. | SANGER | ||
| A431 | Growth Inhibition Assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 4.14081 μM. | SANGER | ||
| EPLC-272H | Growth Inhibition Assay | Inhibition of human EPLC-272H cell growth in a cell viability assay, IC50 = 4.17596 μM. | SANGER | ||
| HT-1376 | Growth Inhibition Assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50 = 4.23059 μM. | SANGER | ||
| HCC1954 | Growth Inhibition Assay | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50 = 4.25746 μM. | SANGER | ||
| KYSE-510 | Growth Inhibition Assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50 = 4.2609 μM. | SANGER | ||
| PANC-03-27 | Growth Inhibition Assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 4.30083 μM. | SANGER | ||
| MDA-MB-157 | Growth Inhibition Assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 4.30656 μM. | SANGER | ||
| HOP-62 | Growth Inhibition Assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50 = 4.30856 μM. | SANGER | ||
| ETK-1 | Growth Inhibition Assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50 = 4.36203 μM. | SANGER | ||
| MIA-PaCa-2 | Growth Inhibition Assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50 = 4.36227 μM. | SANGER | ||
| MHH-PREB-1 | Growth Inhibition Assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50 = 4.39773 μM. | SANGER | ||
| LXF-289 | Growth Inhibition Assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50 = 4.40202 μM. | SANGER | ||
| ATN-1 | Growth Inhibition Assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 4.42341 μM. | SANGER | ||
| 8505C | Growth Inhibition Assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 4.45825 μM. | SANGER | ||
| HOS | Growth Inhibition Assay | Inhibition of human HOS cell growth in a cell viability assay, IC50 = 4.46453 μM. | SANGER | ||
| U-266 | Growth Inhibition Assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 4.61032 μM. | SANGER | ||
| 5637 | Growth Inhibition Assay | Inhibition of human 5637 cell growth in a cell viability assay, IC50 = 4.61444 μM. | SANGER | ||
| GCIY | Growth Inhibition Assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50 = 4.71015 μM. | SANGER | ||
| MDA-MB-231 | Growth Inhibition Assay | Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50 = 4.72115 μM. | SANGER | ||
| RKO | Growth Inhibition Assay | Inhibition of human RKO cell growth in a cell viability assay, IC50 = 4.72817 μM. | SANGER | ||
| COR-L23 | Growth Inhibition Assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50 = 4.74256 μM. | SANGER | ||
| DJM-1 | Growth Inhibition Assay | Inhibition of human DJM-1 cell growth in a cell viability assay, IC50 = 4.79729 μM. | SANGER | ||
| D-423MG | Growth Inhibition Assay | Inhibition of human D-423MG cell growth in a cell viability assay, IC50 = 4.80803 μM. | SANGER | ||
| DMS-114 | Growth Inhibition Assay | Inhibition of human DMS-114 cell growth in a cell viability assay, IC50 = 4.81386 μM. | SANGER | ||
| MHH-ES-1 | Growth Inhibition Assay | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50 = 4.82504 μM. | SANGER | ||
| CAL-51 | Growth Inhibition Assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 4.86843 μM. | SANGER | ||
| SW626 | Growth Inhibition Assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 4.89697 μM. | SANGER | ||
| COLO-824 | Growth Inhibition Assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 4.90408 μM. | SANGER | ||
| NCI-H1437 | Growth Inhibition Assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50 = 4.9293 μM. | SANGER | ||
| CAL-39 | Growth Inhibition Assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50 = 4.93988 μM. | SANGER | ||
| PC-3 | Growth Inhibition Assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50 = 4.94648 μM. | SANGER | ||
| A101D | Growth Inhibition Assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 4.96865 μM. | SANGER | ||
| ES1 | Growth Inhibition Assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50 = 5.0013 μM. | SANGER | ||
| TE-1 | Growth Inhibition Assay | Inhibition of human TE-1 cell growth in a cell viability assay, IC50 = 5.03666 μM. | SANGER | ||
| KP-N-YN | Growth Inhibition Assay | Inhibition of human KP-N-YN cell growth in a cell viability assay, IC50 = 5.0567 μM. | SANGER | ||
| EFO-27 | Growth Inhibition Assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50 = 5.06329 μM. | SANGER | ||
| BT-549 | Growth Inhibition Assay | Inhibition of human BT-549 cell growth in a cell viability assay, IC50 = 5.07736 μM. | SANGER | ||
| HLE | Growth Inhibition Assay | Inhibition of human HLE cell growth in a cell viability assay, IC50 = 5.11734 μM. | SANGER | ||
| SW982 | Growth Inhibition Assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50 = 5.13374 μM. | SANGER | ||
| SCC-25 | Growth Inhibition Assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 5.19046 μM. | SANGER | ||
| SK-MEL-28 | Growth Inhibition Assay | Inhibition of human SK-MEL-28 cell growth in a cell viability assay, IC50 = 5.20313 μM. | SANGER | ||
| CaR-1 | Growth Inhibition Assay | Inhibition of human CaR-1 cell growth in a cell viability assay, IC50 = 5.20726 μM. | SANGER | ||
| MLMA | Growth Inhibition Assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 5.23436 μM. | SANGER | ||
| VM-CUB-1 | Growth Inhibition Assay | Inhibition of human VM-CUB-1 cell growth in a cell viability assay, IC50 = 5.23439 μM. | SANGER | ||
| KNS-42 | Growth Inhibition Assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50 = 5.2616 μM. | SANGER | ||
| TK10 | Growth Inhibition Assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50 = 5.36086 μM. | SANGER | ||
| MEG-01 | Growth Inhibition Assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 5.36274 μM. | SANGER | ||
| DEL | Growth Inhibition Assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 5.39023 μM. | SANGER | ||
| SJRH30 | Growth Inhibition Assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 5.39213 μM. | SANGER | ||
| SK-PN-DW | Growth Inhibition Assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50 = 5.43589 μM. | SANGER | ||
| TE-10 | Growth Inhibition Assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50 = 5.44893 μM. | SANGER | ||
| KNS-81-FD | Growth Inhibition Assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50 = 5.50092 μM. | SANGER | ||
| BHY | Growth Inhibition Assay | Inhibition of human BHY cell growth in a cell viability assay, IC50 = 5.5107 μM. | SANGER | ||
| KYSE-270 | Growth Inhibition Assay | Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50 = 5.53536 μM. | SANGER | ||
| NCI-H650 | Growth Inhibition Assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50 = 5.57114 μM. | SANGER | ||
| L-363 | Growth Inhibition Assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 5.69476 μM. | SANGER | ||
| TCCSUP | Growth Inhibition Assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 5.71778 μM. | SANGER | ||
| SCH | Growth Inhibition Assay | Inhibition of human SCH cell growth in a cell viability assay, IC50 = 5.74767 μM. | SANGER | ||
| HTC-C3 | Growth Inhibition Assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 5.77644 μM. | SANGER | ||
| J-RT3-T3-5 | Growth Inhibition Assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 5.80794 μM. | SANGER | ||
| Hs-578-T | Growth Inhibition Assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 5.83607 μM. | SANGER | ||
| M14 | Growth Inhibition Assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 5.86726 μM. | SANGER | ||
| HT-144 | Growth Inhibition Assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 5.86832 μM. | SANGER | ||
| CAL-54 | Growth Inhibition Assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 5.93314 μM. | SANGER | ||
| T47D | Growth Inhibition Assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 5.9612 μM. | SANGER | ||
| GB-1 | Growth Inhibition Assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 6.02068 μM. | SANGER | ||
| HSC-2 | Growth Inhibition Assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50 = 6.12353 μM. | SANGER | ||
| SiHa | Growth Inhibition Assay | Inhibition of human SiHa cell growth in a cell viability assay, IC50 = 6.14097 μM. | SANGER | ||
| OMC-1 | Growth Inhibition Assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50 = 6.35441 μM. | SANGER | ||
| HGC-27 | Growth Inhibition Assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50 = 6.35786 μM. | SANGER | ||
| FTC-133 | Growth Inhibition Assay | Inhibition of human FTC-133 cell growth in a cell viability assay, IC50 = 6.46551 μM. | SANGER | ||
| KS-1 | Growth Inhibition Assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 6.52147 μM. | SANGER | ||
| HT-1080 | Growth Inhibition Assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50 = 6.54042 μM. | SANGER | ||
| SKG-IIIa | Growth Inhibition Assay | Inhibition of human SKG-IIIa cell growth in a cell viability assay, IC50 = 6.56263 μM. | SANGER | ||
| OCUB-M | Growth Inhibition Assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50 = 6.6077 μM. | SANGER | ||
| MDA-MB-175-VII | Growth Inhibition Assay | Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay, IC50 = 6.6209 μM. | SANGER | ||
| BB30-HNC | Growth Inhibition Assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 6.67444 μM. | SANGER | ||
| D-542MG | Growth Inhibition Assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50 = 6.7309 μM. | SANGER | ||
| NCI-H2405 | Growth Inhibition Assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50 = 6.74855 μM. | SANGER | ||
| SW1573 | Growth Inhibition Assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50 = 6.78319 μM. | SANGER | ||
| NCI-SNU-1 | Growth Inhibition Assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50 = 6.79022 μM. | SANGER | ||
| RT-112 | Growth Inhibition Assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 6.79463 μM. | SANGER | ||
| COR-L88 | Growth Inhibition Assay | Inhibition of human COR-L88 cell growth in a cell viability assay, IC50 = 6.79791 μM. | SANGER | ||
| SCC-9 | Growth Inhibition Assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 6.8255 μM. | SANGER | ||
| U-87-MG | Growth Inhibition Assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 6.83826 μM. | SANGER | ||
| Detroit562 | Growth Inhibition Assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50 = 6.85991 μM. | SANGER | ||
| LC-2-ad | Growth Inhibition Assay | Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50 = 6.86292 μM. | SANGER | ||
| IGROV-1 | Growth Inhibition Assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50 = 6.92583 μM. | SANGER | ||
| OVCAR-8 | Growth Inhibition Assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50 = 6.94229 μM. | SANGER | ||
| SNU-387 | Growth Inhibition Assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 6.99516 μM. | SANGER | ||
| TGBC1TKB | Growth Inhibition Assay | Inhibition of human TGBC1TKB cell growth in a cell viability assay, IC50 = 7.15277 μM. | SANGER | ||
| NOS-1 | Growth Inhibition Assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 7.20415 μM. | SANGER | ||
| HEC-1 | Growth Inhibition Assay | Inhibition of human HEC-1 cell growth in a cell viability assay, IC50 = 7.25387 μM. | SANGER | ||
| GI-ME-N | Growth Inhibition Assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50 = 7.29158 μM. | SANGER | ||
| KYSE-520 | Growth Inhibition Assay | Inhibition of human KYSE-520 cell growth in a cell viability assay, IC50 = 7.2929 μM. | SANGER | ||
| SNU-423 | Growth Inhibition Assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50 = 7.29452 μM. | SANGER | ||
| C-33-A | Growth Inhibition Assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50 = 7.4782 μM. | SANGER | ||
| SK-UT-1 | Growth Inhibition Assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50 = 7.54829 μM. | SANGER | ||
| OVCAR-4 | Growth Inhibition Assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 7.5526 μM. | SANGER | ||
| KYSE-450 | Growth Inhibition Assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50 = 7.63791 μM. | SANGER | ||
| RS4-11 | Growth Inhibition Assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 7.70196 μM. | SANGER | ||
| OVCAR-5 | Growth Inhibition Assay | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50 = 7.82329 μM. | SANGER | ||
| K5 | Growth Inhibition Assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 7.8742 μM. | SANGER | ||
| 786-0 | Growth Inhibition Assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 8.03095 μM. | SANGER | ||
| NCI-H747 | Growth Inhibition Assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 8.04457 μM. | SANGER | ||
| CAL-27 | Growth Inhibition Assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50 = 8.1272 μM. | SANGER | ||
| FADU | Growth Inhibition Assay | Inhibition of human FADU cell growth in a cell viability assay, IC50 = 8.17543 μM. | SANGER | ||
| SW780 | Growth Inhibition Assay | Inhibition of human SW780 cell growth in a cell viability assay, IC50 = 8.18821 μM. | SANGER | ||
| ACHN | Growth Inhibition Assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50 = 8.22529 μM. | SANGER | ||
| TE-6 | Growth Inhibition Assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 8.23788 μM. | SANGER | ||
| NCI-H2087 | Growth Inhibition Assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 8.36158 μM. | SANGER | ||
| NCI-H2122 | Growth Inhibition Assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50 = 8.40479 μM. | SANGER | ||
| SK-LU-1 | Growth Inhibition Assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50 = 8.43997 μM. | SANGER | ||
| 22RV1 | Growth Inhibition Assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 8.61786 μM. | SANGER | ||
| MEL-JUSO | Growth Inhibition Assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 8.68675 μM. | SANGER | ||
| UM-UC-3 | Growth Inhibition Assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50 = 8.7139 μM. | SANGER | ||
| HuH-7 | Growth Inhibition Assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 8.73012 μM. | SANGER | ||
| SNU-449 | Growth Inhibition Assay | Inhibition of human SNU-449 cell growth in a cell viability assay, IC50 = 8.75265 μM. | SANGER | ||
| RVH-421 | Growth Inhibition Assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50 = 8.75398 μM. | SANGER | ||
| MFM-223 | Growth Inhibition Assay | Inhibition of human MFM-223 cell growth in a cell viability assay, IC50 = 8.80735 μM. | SANGER | ||
| CHP-212 | Growth Inhibition Assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50 = 8.82267 μM. | SANGER | ||
| NCI-H28 | Growth Inhibition Assay | Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50 = 8.85185 μM. | SANGER | ||
| C8166 | Growth Inhibition Assay | Inhibition of human C8166 cell growth in a cell viability assay, IC50 = 8.86772 μM. | SANGER | ||
| SCC-15 | Growth Inhibition Assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50 = 8.87196 μM. | SANGER | ||
| DMS-273 | Growth Inhibition Assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50 = 8.89623 μM. | SANGER | ||
| MPP-89 | Growth Inhibition Assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 8.91341 μM. | SANGER | ||
| EW-22 | Growth Inhibition Assay | Inhibition of human EW-22 cell growth in a cell viability assay, IC50 = 8.91382 μM. | SANGER | ||
| RCM-1 | Growth Inhibition Assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50 = 8.96486 μM. | SANGER | ||
| BT-474 | Growth Inhibition Assay | Inhibition of human BT-474 cell growth in a cell viability assay, IC50 = 8.98872 μM. | SANGER | ||
| TI-73 | Growth Inhibition Assay | Inhibition of human TI-73 cell growth in a cell viability assay, IC50 = 9.03496 μM. | SANGER | ||
| ES3 | Growth Inhibition Assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50 = 9.05156 μM. | SANGER | ||
| NB17 | Growth Inhibition Assay | Inhibition of human NB17 cell growth in a cell viability assay, IC50 = 9.14535 μM. | SANGER | ||
| MOLT-16 | Growth Inhibition Assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 9.16655 μM. | SANGER | ||
| TGBC11TKB | Growth Inhibition Assay | Inhibition of human TGBC11TKB cell growth in a cell viability assay, IC50 = 9.19205 μM. | SANGER | ||
| NB12 | Growth Inhibition Assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 9.34081 μM. | SANGER | ||
| MEL-HO | Growth Inhibition Assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50 = 9.402 μM. | SANGER | ||
| HuCCT1 | Growth Inhibition Assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 9.47406 μM. | SANGER | ||
| A704 | Growth Inhibition Assay | Inhibition of human A704 cell growth in a cell viability assay, IC50 = 9.47745 μM. | SANGER | ||
| SW756 | Growth Inhibition Assay | Inhibition of human SW756 cell growth in a cell viability assay, IC50 = 9.55361 μM. | SANGER | ||
| SAS | Growth Inhibition Assay | Inhibition of human SAS cell growth in a cell viability assay, IC50 = 9.58455 μM. | SANGER | ||
| KINGS-1 | Growth Inhibition Assay | Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50 = 9.6937 μM. | SANGER | ||
| NKM-1 | Growth Inhibition Assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50 = 9.83964 μM. | SANGER | ||
| C2BBe1 | Growth Inhibition Assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50 = 9.86204 μM. | SANGER | ||
| A204 | Growth Inhibition Assay | Inhibition of human A204 cell growth in a cell viability assay, IC50 = 9.89755 μM. | SANGER | ||
| G-401 | Growth Inhibition Assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50 = 9.90449 μM. | SANGER | ||
| PFSK-1 | Growth Inhibition Assay | Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50 = 9.95669 μM. | SANGER | ||
| KYSE-410 | Growth Inhibition Assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50 = 10.0615 μM. | SANGER | ||
| SK-MEL-2 | Growth Inhibition Assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50 = 10.1588 μM. | SANGER | ||
| NB5 | Growth Inhibition Assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50 = 10.5405 μM. | SANGER | ||
| NTERA-S-cl-D1 | Growth Inhibition Assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50 = 10.5475 μM. | SANGER | ||
| MZ2-MEL | Growth Inhibition Assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 10.662 μM. | SANGER | ||
| SF539 | Growth Inhibition Assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 10.7188 μM. | SANGER | ||
| CAL-120 | Growth Inhibition Assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50 = 10.7597 μM. | SANGER | ||
| GR-ST | Growth Inhibition Assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 11.298 μM. | SANGER | ||
| IA-LM | Growth Inhibition Assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 11.3486 μM. | SANGER | ||
| NCI-H2452 | Growth Inhibition Assay | Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50 = 11.3927 μM. | SANGER | ||
| NCI-H1648 | Growth Inhibition Assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 11.4629 μM. | SANGER | ||
| YH-13 | Growth Inhibition Assay | Inhibition of human YH-13 cell growth in a cell viability assay, IC50 = 11.4742 μM. | SANGER | ||
| NCI-H2228 | Growth Inhibition Assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 11.4928 μM. | SANGER | ||
| LN-405 | Growth Inhibition Assay | Inhibition of human LN-405 cell growth in a cell viability assay, IC50 = 11.5927 μM. | SANGER | ||
| 647-V | Growth Inhibition Assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50 = 11.5974 μM. | SANGER | ||
| HCC1806 | Growth Inhibition Assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50 = 11.6134 μM. | SANGER | ||
| HPAF-II | Growth Inhibition Assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 11.8356 μM. | SANGER | ||
| BB49-HNC | Growth Inhibition Assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 11.8375 μM. | SANGER | ||
| KGN | Growth Inhibition Assay | Inhibition of human KGN cell growth in a cell viability assay, IC50 = 11.859 μM. | SANGER | ||
| NOMO-1 | Growth Inhibition Assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 11.8597 μM. | SANGER | ||
| A388 | Growth Inhibition Assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 11.8808 μM. | SANGER | ||
| Saos-2 | Growth Inhibition Assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50 = 12.2004 μM. | SANGER | ||
| SK-HEP-1 | Growth Inhibition Assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50 = 12.2613 μM. | SANGER | ||
| HCE-4 | Growth Inhibition Assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 12.27 μM. | SANGER | ||
| NCI-H1581 | Growth Inhibition Assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 12.2819 μM. | SANGER | ||
| NCI-H23 | Growth Inhibition Assay | Inhibition of human NCI-H23 cell growth in a cell viability assay, IC50 = 12.3125 μM. | SANGER | ||
| NCI-H596 | Growth Inhibition Assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50 = 12.4798 μM. | SANGER | ||
| NB69 | Growth Inhibition Assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 12.7585 μM. | SANGER | ||
| ChaGo-K-1 | Growth Inhibition Assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50 = 12.7649 μM. | SANGER | ||
| EFM-19 | Growth Inhibition Assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50 = 12.7717 μM. | SANGER | ||
| SW962 | Growth Inhibition Assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 12.8223 μM. | SANGER | ||
| KALS-1 | Growth Inhibition Assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50 = 13.095 μM. | SANGER | ||
| MDA-MB-415 | Growth Inhibition Assay | Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50 = 13.1609 μM. | SANGER | ||
| SW684 | Growth Inhibition Assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50 = 13.1861 μM. | SANGER | ||
| NCI-H2052 | Growth Inhibition Assay | Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50 = 13.3848 μM. | SANGER | ||
| HOP-92 | Growth Inhibition Assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50 = 13.7996 μM. | SANGER | ||
| OE19 | Growth Inhibition Assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50 = 14.0075 μM. | SANGER | ||
| D-392MG | Growth Inhibition Assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50 = 14.1211 μM. | SANGER | ||
| A253 | Growth Inhibition Assay | Inhibition of human A253 cell growth in a cell viability assay, IC50 = 14.225 μM. | SANGER | ||
| NCI-H1155 | Growth Inhibition Assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50 = 14.2747 μM. | SANGER | ||
| SNB75 | Growth Inhibition Assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50 = 14.3893 μM. | SANGER | ||
| 23132-87 | Growth Inhibition Assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50 = 14.8353 μM. | SANGER | ||
| Calu-3 | Growth Inhibition Assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50 = 14.8743 μM. | SANGER | ||
| CW-2 | Growth Inhibition Assay | Inhibition of human CW-2 cell growth in a cell viability assay, IC50 = 15.0223 μM. | SANGER | ||
| COLO-679 | Growth Inhibition Assay | Inhibition of human COLO-679 cell growth in a cell viability assay, IC50 = 15.1013 μM. | SANGER | ||
| NCI-SNU-5 | Growth Inhibition Assay | Inhibition of human NCI-SNU-5 cell growth in a cell viability assay, IC50 = 15.5589 μM. | SANGER | ||
| AN3-CA | Growth Inhibition Assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 15.6468 μM. | SANGER | ||
| SF126 | Growth Inhibition Assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50 = 15.7285 μM. | SANGER | ||
| D-247MG | Growth Inhibition Assay | Inhibition of human D-247MG cell growth in a cell viability assay, IC50 = 15.8534 μM. | SANGER | ||
| UACC-62 | Growth Inhibition Assay | Inhibition of human UACC-62 cell growth in a cell viability assay, IC50 = 15.966 μM. | SANGER | ||
| GP5d | Growth Inhibition Assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50 = 16.1171 μM. | SANGER | ||
| HuO-3N1 | Growth Inhibition Assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 16.2473 μM. | SANGER | ||
| NCI-H1092 | Growth Inhibition Assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 16.6297 μM. | SANGER | ||
| HCC1187 | Growth Inhibition Assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 16.6557 μM. | SANGER | ||
| G-402 | Growth Inhibition Assay | Inhibition of human G-402 cell growth in a cell viability assay, IC50 = 16.8565 μM. | SANGER | ||
| HT55 | Growth Inhibition Assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 16.8751 μM. | SANGER | ||
| NCI-H2009 | Growth Inhibition Assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50 = 16.9266 μM. | SANGER | ||
| SH-4 | Growth Inhibition Assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 16.992 μM. | SANGER | ||
| SW1783 | Growth Inhibition Assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 16.9998 μM. | SANGER | ||
| HT | Growth Inhibition Assay | Inhibition of human HT cell growth in a cell viability assay, IC50 = 17.1964 μM. | SANGER | ||
| CP66-MEL | Growth Inhibition Assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50 = 17.301 μM. | SANGER | ||
| BEN | Growth Inhibition Assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 17.5626 μM. | SANGER | ||
| HCC38 | Growth Inhibition Assay | Inhibition of human HCC38 cell growth in a cell viability assay, IC50 = 17.7698 μM. | SANGER | ||
| LAN-6 | Growth Inhibition Assay | Inhibition of human LAN-6 cell growth in a cell viability assay, IC50 = 17.8485 μM. | SANGER | ||
| RERF-LC-MS | Growth Inhibition Assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50 = 17.9129 μM. | SANGER | ||
| NCI-H1770 | Growth Inhibition Assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50 = 17.9491 μM. | SANGER | ||
| LCLC-103H | Growth Inhibition Assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50 = 18.051 μM. | SANGER | ||
| NCI-H520 | Growth Inhibition Assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50 = 18.3282 μM. | SANGER | ||
| LU-65 | Growth Inhibition Assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 18.4043 μM. | SANGER | ||
| SK-MEL-3 | Growth Inhibition Assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 18.668 μM. | SANGER | ||
| LK-2 | Growth Inhibition Assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 18.7723 μM. | SANGER | ||
| PANC-08-13 | Growth Inhibition Assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 18.7889 μM. | SANGER | ||
| NCI-H460 | Growth Inhibition Assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50 = 18.8467 μM. | SANGER | ||
| COLO-684 | Growth Inhibition Assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 18.9956 μM. | SANGER | ||
| RPMI-2650 | Growth Inhibition Assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50 = 19.012 μM. | SANGER | ||
| NY | Growth Inhibition Assay | Inhibition of human NY cell growth in a cell viability assay, IC50 = 19.1567 μM. | SANGER | ||
| NB7 | Growth Inhibition Assay | Inhibition of human NB7 cell growth in a cell viability assay, IC50 = 19.1753 μM. | SANGER | ||
| NCI-H358 | Growth Inhibition Assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 19.2673 μM. | SANGER | ||
| MC116 | Growth Inhibition Assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50 = 19.533 μM. | SANGER | ||
| MS-1 | Growth Inhibition Assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 19.6103 μM. | SANGER | ||
| NCI-H82 | Growth Inhibition Assay | Inhibition of human NCI-H82 cell growth in a cell viability assay, IC50 = 19.6878 μM. | SANGER | ||
| OCI-AML2 | Growth Inhibition Assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 19.7032 μM. | SANGER | ||
| LS-123 | Growth Inhibition Assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50 = 20.0194 μM. | SANGER | ||
| PC-14 | Growth Inhibition Assay | Inhibition of human PC-14 cell growth in a cell viability assay, IC50 = 20.1834 μM. | SANGER | ||
| NCI-H1703 | Growth Inhibition Assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 20.8173 μM. | SANGER | ||
| Calu-6 | Growth Inhibition Assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50 = 21.1005 μM. | SANGER | ||
| no-11 | Growth Inhibition Assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50 = 21.1602 μM. | SANGER | ||
| NCI-H727 | Growth Inhibition Assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 21.3493 μM. | SANGER | ||
| DSH1 | Growth Inhibition Assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50 = 21.3879 μM. | SANGER | ||
| KYSE-140 | Growth Inhibition Assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50 = 21.7271 μM. | SANGER | ||
| RH-1 | Growth Inhibition Assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50 = 21.883 μM. | SANGER | ||
| HAL-01 | Growth Inhibition Assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50 = 22.0419 μM. | SANGER | ||
| RXF393 | Growth Inhibition Assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50 = 22.2788 μM. | SANGER | ||
| LS-411N | Growth Inhibition Assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 22.2869 μM. | SANGER | ||
| no-10 | Growth Inhibition Assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50 = 22.5004 μM. | SANGER | ||
| MKN7 | Growth Inhibition Assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50 = 22.6869 μM. | SANGER | ||
| AU565 | Growth Inhibition Assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50 = 22.7478 μM. | SANGER | ||
| NUGC-3 | Growth Inhibition Assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 23.1199 μM. | SANGER | ||
| EW-16 | Growth Inhibition Assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50 = 24.0926 μM. | SANGER | ||
| HCC70 | Growth Inhibition Assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 24.1323 μM. | SANGER | ||
| RPMI-8226 | Growth Inhibition Assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50 = 24.3155 μM. | SANGER | ||
| CFPAC-1 | Growth Inhibition Assay | Inhibition of human CFPAC-1 cell growth in a cell viability assay, IC50 = 24.6272 μM. | SANGER | ||
| DoTc2-4510 | Growth Inhibition Assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50 = 24.7575 μM. | SANGER | ||
| KNS-62 | Growth Inhibition Assay | Inhibition of human KNS-62 cell growth in a cell viability assay, IC50 = 25.018 μM. | SANGER | ||
| SK-N-DZ | Growth Inhibition Assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 25.0904 μM. | SANGER | ||
| CAL-85-1 | Growth Inhibition Assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 25.1544 μM. | SANGER | ||
| JVM-2 | Growth Inhibition Assay | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50 = 25.2122 μM. | SANGER | ||
| NCI-H2347 | Growth Inhibition Assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 25.4248 μM. | SANGER | ||
| P30-OHK | Growth Inhibition Assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 25.6318 μM. | SANGER | ||
| SK-N-FI | Growth Inhibition Assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50 = 26.1162 μM. | SANGER | ||
| CAMA-1 | Growth Inhibition Assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50 = 26.4876 μM. | SANGER | ||
| MHH-NB-11 | Growth Inhibition Assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 26.5851 μM. | SANGER | ||
| IST-MEL1 | Growth Inhibition Assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 26.7177 μM. | SANGER | ||
| KARPAS-299 | Growth Inhibition Assay | Inhibition of human KARPAS-299 cell growth in a cell viability assay, IC50 = 27.4702 μM. | SANGER | ||
| TE-11 | Growth Inhibition Assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 27.7342 μM. | SANGER | ||
| 769-P | Growth Inhibition Assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 28.4533 μM. | SANGER | ||
| CAL-72 | Growth Inhibition Assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 28.5561 μM. | SANGER | ||
| NCI-H2342 | Growth Inhibition Assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 29.3803 μM. | SANGER | ||
| NCI-H1651 | Growth Inhibition Assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 29.8503 μM. | SANGER | ||
| OE33 | Growth Inhibition Assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50 = 30.1342 μM. | SANGER | ||
| HuP-T4 | Growth Inhibition Assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50 = 31.4837 μM. | SANGER | ||
| U-118-MG | Growth Inhibition Assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 32.5441 μM. | SANGER | ||
| SN12C | Growth Inhibition Assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50 = 32.8815 μM. | SANGER | ||
| TE-5 | Growth Inhibition Assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50 = 33.1368 μM. | SANGER | ||
| KM-H2 | Growth Inhibition Assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 33.1699 μM. | SANGER | ||
| OVCAR-3 | Growth Inhibition Assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 33.4127 μM. | SANGER | ||
| NCI-H1304 | Growth Inhibition Assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50 = 33.6036 μM. | SANGER | ||
| LU-135 | Growth Inhibition Assay | Inhibition of human LU-135 cell growth in a cell viability assay, IC50 = 33.7086 μM. | SANGER | ||
| S-117 | Growth Inhibition Assay | Inhibition of human S-117 cell growth in a cell viability assay, IC50 = 33.7286 μM. | SANGER | ||
| NCI-H1755 | Growth Inhibition Assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 33.811 μM. | SANGER | ||
| SK-OV-3 | Growth Inhibition Assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50 = 33.8854 μM. | SANGER | ||
| RCC10RGB | Growth Inhibition Assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 33.9433 μM. | SANGER | ||
| COLO-680N | Growth Inhibition Assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50 = 34.1397 μM. | SANGER | ||
| KURAMOCHI | Growth Inhibition Assay | Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50 = 34.6425 μM. | SANGER | ||
| NCI-H661 | Growth Inhibition Assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50 = 34.8448 μM. | SANGER | ||
| YAPC | Growth Inhibition Assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 35.9533 μM. | SANGER | ||
| NCI-H526 | Growth Inhibition Assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 37.2772 μM. | SANGER | ||
| A498 | Growth Inhibition Assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 38.0954 μM. | SANGER | ||
| VMRC-RCZ | Growth Inhibition Assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50 = 39.0054 μM. | SANGER | ||
| HCT-116 | Growth Inhibition Assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 39.058 μM. | SANGER | ||
| COLO-320-HSR | Growth Inhibition Assay | Inhibition of human COLO-320-HSR cell growth in a cell viability assay, IC50 = 40.041 μM. | SANGER | ||
| OAW-42 | Growth Inhibition Assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50 = 40.0542 μM. | SANGER | ||
| SK-MEL-1 | Growth Inhibition Assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50 = 40.2927 μM. | SANGER | ||
| IST-MES1 | Growth Inhibition Assay | Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50 = 40.7653 μM. | SANGER | ||
| CP50-MEL-B | Growth Inhibition Assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50 = 41.0797 μM. | SANGER | ||
| RMG-I | Growth Inhibition Assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50 = 42.4921 μM. | SANGER | ||
| D-336MG | Growth Inhibition Assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50 = 43.1152 μM. | SANGER | ||
| SHP-77 | Growth Inhibition Assay | Inhibition of human SHP-77 cell growth in a cell viability assay, IC50 = 43.1828 μM. | SANGER | ||
| SW872 | Growth Inhibition Assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50 = 43.2123 μM. | SANGER | ||
| DBTRG-05MG | Growth Inhibition Assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50 = 44.6996 μM. | SANGER | ||
| COLO-678 | Growth Inhibition Assay | Inhibition of human COLO-678 cell growth in a cell viability assay, IC50 = 45.7032 μM. | SANGER | ||
| EGI-1 | Growth Inhibition Assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50 = 47.1833 μM. | SANGER | ||
| KYSE-70 | Growth Inhibition Assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50 = 47.7222 μM. | SANGER | ||
| BALL-1 | Growth Inhibition Assay | Inhibition of human BALL-1 cell growth in a cell viability assay, IC50 = 47.8254 μM. | SANGER | ||
| MDA-MB-361 | Growth Inhibition Assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 48.046 μM. | SANGER | ||
| NCI-H1838 | Growth Inhibition Assay | Inhibition of human NCI-H1838 cell growth in a cell viability assay, IC50 = 48.3458 μM. | SANGER | ||
| NCI-H1573 | Growth Inhibition Assay | Inhibition of human NCI-H1573 cell growth in a cell viability assay, IC50 = 48.6785 μM. | SANGER | ||
| HCC1395 | Growth Inhibition Assay | Inhibition of human HCC1395 cell growth in a cell viability assay, IC50 = 48.9919 μM. | SANGER | ||
| NCI-H2291 | Growth Inhibition Assay | Inhibition of human NCI-H2291 cell growth in a cell viability assay, IC50 = 49.5988 μM. | SANGER | ||
| RH-18 | Growth Inhibition Assay | Inhibition of human RH-18 cell growth in a cell viability assay, IC50 = 50.0884 μM. | SANGER | ||
| LU-99A | Growth Inhibition Assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 51.6128 μM. | SANGER | ||
| NCI-H1693 | Growth Inhibition Assay | Inhibition of human NCI-H1693 cell growth in a cell viability assay, IC50 = 52.0101 μM. | SANGER | ||
| TE-12 | Growth Inhibition Assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50 = 52.3319 μM. | SANGER | ||
| MCF7 | Growth Inhibition Assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 52.8847 μM. | SANGER | ||
| MMAC-SF | Growth Inhibition Assay | Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50 = 53.558 μM. | SANGER | ||
| COLO-792 | Growth Inhibition Assay | Inhibition of human COLO-792 cell growth in a cell viability assay, IC50 = 53.686 μM. | SANGER | ||
| MKN28 | Growth Inhibition Assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 54.4187 μM. | SANGER | ||
| PA-1 | Growth Inhibition Assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50 = 54.6183 μM. | SANGER | ||
| SW1088 | Growth Inhibition Assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 56.932 μM. | SANGER | ||
| NB13 | Growth Inhibition Assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50 = 57.5442 μM. | SANGER | ||
| KLE | Growth Inhibition Assay | Inhibition of human KLE cell growth in a cell viability assay, IC50 = 58.3946 μM. | SANGER | ||
| KYSE-180 | Growth Inhibition Assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 58.7833 μM. | SANGER | ||
| NCI-H1355 | Growth Inhibition Assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 59.2853 μM. | SANGER | ||
| LB2518-MEL | Growth Inhibition Assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50 = 59.8763 μM. | SANGER | ||
| MFE-280 | Growth Inhibition Assay | Inhibition of human MFE-280 cell growth in a cell viability assay, IC50 = 60.9372 μM. | SANGER | ||
| ALL-PO | Growth Inhibition Assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 61.2463 μM. | SANGER | ||
| NCI-H1650 | Growth Inhibition Assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 62.3298 μM. | SANGER | ||
| HCC2218 | Growth Inhibition Assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50 = 63.3887 μM. | SANGER | ||
| UMC-11 | Growth Inhibition Assay | Inhibition of human UMC-11 cell growth in a cell viability assay, IC50 = 65.4468 μM. | SANGER | ||
| CCRF-CEM | Growth Inhibition Assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 65.4541 μM. | SANGER | ||
| NCI-H2030 | Growth Inhibition Assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50 = 66.5634 μM. | SANGER | ||
| EKVX | Growth Inhibition Assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50 = 68.1743 μM. | SANGER | ||
| MSTO-211H | Growth Inhibition Assay | Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50 = 68.4406 μM. | SANGER | ||
| A2058 | Growth Inhibition Assay | Inhibition of human A2058 cell growth in a cell viability assay, IC50 = 68.4821 μM. | SANGER | ||
| MG-63 | Growth Inhibition Assay | Inhibition of human MG-63 cell growth in a cell viability assay, IC50 = 69.7565 μM. | SANGER | ||
| NCI-H630 | Growth Inhibition Assay | Inhibition of human NCI-H630 cell growth in a cell viability assay, IC50 = 70.4213 μM. | SANGER | ||
| HCC1569 | Growth Inhibition Assay | Inhibition of human HCC1569 cell growth in a cell viability assay, IC50 = 71.0089 μM. | SANGER | ||
| Capan-2 | Growth Inhibition Assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 71.0614 μM. | SANGER | ||
| NCI-H2126 | Growth Inhibition Assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 73.4725 μM. | SANGER | ||
| OS-RC-2 | Growth Inhibition Assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50 = 73.6568 μM. | SANGER | ||
| COLO-741 | Growth Inhibition Assay | Inhibition of human COLO-741 cell growth in a cell viability assay, IC50 = 78.9707 μM. | SANGER | ||
| ES6 | Growth Inhibition Assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50 = 79.1431 μM. | SANGER | ||
| VA-ES-BJ | Growth Inhibition Assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50 = 80.7811 μM. | SANGER | ||
| Mewo | Growth Inhibition Assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 80.9653 μM. | SANGER | ||
| EW-13 | Growth Inhibition Assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50 = 82.0084 μM. | SANGER | ||
| SK-MEL-30 | Growth Inhibition Assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 82.0855 μM. | SANGER | ||
| MFH-ino | Growth Inhibition Assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50 = 83.5284 μM. | SANGER | ||
| SW1116 | Growth Inhibition Assay | Inhibition of human SW1116 cell growth in a cell viability assay, IC50 = 85.4856 μM. | SANGER | ||
| LS-513 | Growth Inhibition Assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50 = 88.7976 μM. | SANGER | ||
| SW1463 | Growth Inhibition Assay | Inhibition of human SW1463 cell growth in a cell viability assay, IC50 = 91.6713 μM. | SANGER | ||
| WM-115 | Growth Inhibition Assay | Inhibition of human WM-115 cell growth in a cell viability assay, IC50 = 92.9267 μM. | SANGER | ||
| A2780 | Growth Inhibition Assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50 = 93.6595 μM. | SANGER | ||
| PANC-10-05 | Growth Inhibition Assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50 = 93.9708 μM. | SANGER | ||
| NCI-H1623 | Growth Inhibition Assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50 = 95.7976 μM. | SANGER | ||
| COLO-668 | Growth Inhibition Assay | Inhibition of human COLO-668 cell growth in a cell viability assay, IC50 = 96.9094 μM. | SANGER | ||
| HCC2157 | Growth Inhibition Assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50 = 97.0782 μM. | SANGER | ||
| OC-314 | Growth Inhibition Assay | Inhibition of human OC-314 cell growth in a cell viability assay, IC50 = 98.494 μM. | SANGER | ||
| SK-MEL-24 | Growth Inhibition Assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 99.3301 μM. | SANGER | ||
| HCC2998 | Growth Inhibition Assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50 = 101.05 μM. | SANGER | ||
| NCI-H2170 | Growth Inhibition Assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50 = 102.933 μM. | SANGER | ||
| HT-1197 | Growth Inhibition Assay | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50 = 103.494 μM. | SANGER | ||
| HCT-15 | Growth Inhibition Assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50 = 105.399 μM. | SANGER | ||
| MKN45 | Growth Inhibition Assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 105.597 μM. | SANGER | ||
| SW13 | Growth Inhibition Assay | Inhibition of human SW13 cell growth in a cell viability assay, IC50 = 105.968 μM. | SANGER | ||
| RO82-W-1 | Growth Inhibition Assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50 = 107.765 μM. | SANGER | ||
| JAR | Growth Inhibition Assay | Inhibition of human JAR cell growth in a cell viability assay, IC50 = 108.694 μM. | SANGER | ||
| ESS-1 | Growth Inhibition Assay | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50 = 114.118 μM. | SANGER | ||
| LS-1034 | Growth Inhibition Assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 118.609 μM. | SANGER | ||
| BFTC-909 | Growth Inhibition Assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50 = 120.485 μM. | SANGER | ||
| TGBC24TKB | Growth Inhibition Assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 124.298 μM. | SANGER | ||
| T-24 | Growth Inhibition Assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50 = 125.66 μM. | SANGER | ||
| J82 | Growth Inhibition Assay | Inhibition of human J82 cell growth in a cell viability assay, IC50 = 129.014 μM. | SANGER | ||
| AM-38 | Growth Inhibition Assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 129.407 μM. | SANGER | ||
| MDA-MB-453 | Growth Inhibition Assay | Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50 = 130.177 μM. | SANGER | ||
| U-2-OS | Growth Inhibition Assay | Inhibition of human U-2-OS cell growth in a cell viability assay, IC50 = 130.803 μM. | SANGER | ||
| NCI-H1666 | Growth Inhibition Assay | Inhibition of human NCI-H1666 cell growth in a cell viability assay, IC50 = 131.615 μM. | SANGER | ||
| DOHH-2 | Growth Inhibition Assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50 = 131.981 μM. | SANGER | ||
| U031 | Growth Inhibition Assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 139.51 μM. | SANGER | ||
| A673 | Growth Inhibition Assay | Inhibition of human A673 cell growth in a cell viability assay, IC50 = 140.714 μM. | SANGER | ||
| NCI-H1793 | Growth Inhibition Assay | Inhibition of human NCI-H1793 cell growth in a cell viability assay, IC50 = 142.235 μM. | SANGER | ||
| BxPC-3 | Growth Inhibition Assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 144.449 μM. | SANGER | ||
| SW837 | Growth Inhibition Assay | Inhibition of human SW837 cell growth in a cell viability assay, IC50 = 145.887 μM. | SANGER | ||
| HT-29 | Growth Inhibition Assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50 = 148.287 μM. | SANGER | ||
| MZ7-mel | Growth Inhibition Assay | Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50 = 149.332 μM. | SANGER | ||
| SW620 | Growth Inhibition Assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50 = 152.783 μM. | SANGER | ||
| GAK | Growth Inhibition Assay | Inhibition of human GAK cell growth in a cell viability assay, IC50 = 157.274 μM. | SANGER | ||
| CAS-1 | Growth Inhibition Assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 161.861 μM. | SANGER | ||
| HuP-T3 | Growth Inhibition Assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 164.025 μM. | SANGER | ||
| K-562 | Growth Inhibition Assay | Inhibition of human K-562 cell growth in a cell viability assay, IC50 = 166.999 μM. | SANGER | ||
| KP-4 | Growth Inhibition Assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50 = 176.133 μM. | SANGER | ||
| LB771-HNC | Growth Inhibition Assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 177.514 μM. | SANGER | ||
| BCPAP | Growth Inhibition Assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50 = 178.122 μM. | SANGER | ||
| NCI-N87 | Growth Inhibition Assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50 = 181.488 μM. | SANGER | ||
| H-EMC-SS | Growth Inhibition Assay | Inhibition of human H-EMC-SS cell growth in a cell viability assay, IC50 = 202.692 μM. | SANGER | ||
| D-263MG | Growth Inhibition Assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50 = 207.067 μM. | SANGER | ||
| LB373-MEL-D | Growth Inhibition Assay | Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50 = 207.487 μM. | SANGER | ||
| SF295 | Growth Inhibition Assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50 = 212.709 μM. | SANGER | ||
| BT-20 | Growth Inhibition Assay | Inhibition of human BT-20 cell growth in a cell viability assay, IC50 = 214.977 μM. | SANGER | ||
| SK-LMS-1 | Growth Inhibition Assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50 = 217.946 μM. | SANGER | ||
| HCE-T | Growth Inhibition Assay | Inhibition of human HCE-T cell growth in a cell viability assay, IC50 = 220.414 μM. | SANGER | ||
| NCI-H522 | Growth Inhibition Assay | Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50 = 220.593 μM. | SANGER | ||
| DK-MG | Growth Inhibition Assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50 = 228.077 μM. | SANGER | ||
| HDLM-2 | Growth Inhibition Assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 228.889 μM. | SANGER | ||
| RPMI-8866 | Growth Inhibition Assay | Inhibition of human RPMI-8866 cell growth in a cell viability assay, IC50 = 234.422 μM. | SANGER | ||
| SBC-5 | Growth Inhibition Assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50 = 235.457 μM. | SANGER | ||
| NCI-H441 | Growth Inhibition Assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50 = 241.801 μM. | SANGER | ||
| HCC1937 | Growth Inhibition Assay | Inhibition of human HCC1937 cell growth in a cell viability assay, IC50 = 244.754 μM. | SANGER | ||
| CAKI-1 | Growth Inhibition Assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50 = 256.034 μM. | SANGER | ||
| SW1417 | Growth Inhibition Assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 259.036 μM. | SANGER | ||
| ONS-76 | Growth Inhibition Assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50 = 265.052 μM. | SANGER | ||
| HCC1419 | Growth Inhibition Assay | Inhibition of human HCC1419 cell growth in a cell viability assay, IC50 = 266.025 μM. | SANGER | ||
| A4-Fuk | Growth Inhibition Assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50 = 266.655 μM. | SANGER | ||
| SW1990 | Growth Inhibition Assay | Inhibition of human SW1990 cell growth in a cell viability assay, IC50 = 270.481 μM. | SANGER | ||
| EFO-21 | Growth Inhibition Assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50 = 279.176 μM. | SANGER | ||
| COR-L105 | Growth Inhibition Assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 303.984 μM. | SANGER | ||
| AsPC-1 | Growth Inhibition Assay | Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50 = 316.889 μM. | SANGER | ||
| T84 | Growth Inhibition Assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 325.443 μM. | SANGER | ||
| ABC-1 | Growth Inhibition Assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50 = 335.897 μM. | SANGER | ||
| NCI-H226 | Growth Inhibition Assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 366.683 μM. | SANGER | ||
| UACC-893 | Growth Inhibition Assay | Inhibition of human UACC-893 cell growth in a cell viability assay, IC50 = 368.948 μM. | SANGER | ||
| OAW-28 | Growth Inhibition Assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50 = 383.493 μM. | SANGER | ||
| NMC-G1 | Growth Inhibition Assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50 = 395.947 μM. | SANGER | ||
| NCI-H1563 | Growth Inhibition Assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 398.096 μM. | SANGER | ||
| SW900 | Growth Inhibition Assay | Inhibition of human SW900 cell growth in a cell viability assay, IC50 = 401.326 μM. | SANGER | ||
| SW948 | Growth Inhibition Assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 411.094 μM. | SANGER | ||
| CAPAN-1 | Growth Inhibition Assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 411.292 μM. | SANGER | ||
| UACC-257 | Growth Inhibition Assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 433.155 μM. | SANGER | ||
| ZR-75-30 | Growth Inhibition Assay | Inhibition of human ZR-75-30 cell growth in a cell viability assay, IC50 = 449.934 μM. | SANGER | ||
| NCI-H1993 | Growth Inhibition Assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50 = 480.264 μM. | SANGER | ||
| LB996-RCC | Growth Inhibition Assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50 = 495.241 μM. | SANGER | ||
| L-428 | Growth Inhibition Assay | Inhibition of human L-428 cell growth in a cell viability assay, IC50 = 554.78 μM. | SANGER | ||
| C3A | Growth Inhibition Assay | Inhibition of human C3A cell growth in a cell viability assay, IC50 = 563.78 μM. | SANGER | ||
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | BI-D1870是一種ATP-競爭性S6 ribosome抑制劑，在無細胞試驗中作用于RSK1/2/3/K4，IC50分別為31 nM/24 nM/18 nM/15 nM，作用于RSK比作用于MST2，GSK-3β，MARK3，CK1和Aurora B選擇性高10到100倍。BI-D1870 顯示除了抗癌的屬性包括活性氧的生成、提高內(nèi)質(zhì)網(wǎng)應(yīng)激反應(yīng)和誘導(dǎo)自噬。 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 靶點 |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | BI-D1870抑制RSK1，RSK2，RSK3和RSK4，IC50為10-30 nM，但在100倍更高濃度時，也不顯著抑制10種其他AGC激酶成員和40多個其他蛋白激酶。BI-D1870可滲透細胞的，作用于人類胚胎腎293細胞和大鼠-2細胞，可抑制RSK介導(dǎo)佛波酯和EGF誘導(dǎo)的糖原合酶激酶-3β和LKB1的磷酸化。BI-D1870作用于六種其他AGC激酶，不影響激動劑觸發(fā)的底物磷酸化。而且，BI-D1870不抑制佛波酯或EGF誘導(dǎo)的CREB磷酸化。[1] |
|||
|---|---|---|---|---|
| 實驗圖片 | 檢測方法 | 檢測指標(biāo) | 實驗圖片 | PMID |
| Western blot | p-GSK3 / p-ERK / ERK / p-CREB / CREB / p-S6 / p-LKB1 / LKB1 p-YB1 / YB1 / p-Bad / Bad / p-RSK / RSK IRF4 / MYC / MCL-1 / PARP p-GSK3 / p-ERK / ERK / p-CREB / CREB / p-S6 / p-LKB1 / LKB1 p-YB1 / YB1 / p-Bad / Bad / p-RSK / RSK IRF4 / MYC / MCL-1 / PARP |
|
17040210 | |
| Immunofluorescence | PDCD4 / F-actin PDCD4 / F-actin |
|
25002506 | |
| Growth inhibition assay | Cell viability Cell viability |
|
28415756 | |
化學(xué)信息&溶解度
| 分子量 | 391.42 | 分子式 | C19H23F2N5O2 |
| CAS號 | 501437-28-1 | SDF | Download BI-D1870 SDF |
| Smiles | CC1C(=O)N(C2=CN=C(N=C2N1CCC(C)C)NC3=CC(=C(C(=C3)F)O)F)C | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 78 mg/mL ( (199.27 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 | ||||
實驗計算
動物體內(nèi)配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
常見問題及建議解決方法
問題 1:
BI-D1870 (catalog No.S2843) is found as a racemic mixture?
回答：
Yes, BI-D1870 (catalog No.S2843) is found as a racemic mixture.
Tags: buy BI-D1870 | BI-D1870 supplier | purchase BI-D1870 | BI-D1870 cost | BI-D1870 manufacturer | order BI-D1870 | BI-D1870 distributor
